SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 (In mice)
nature.com
nature.com
> Here we used a single experimental platform based on human lung-only mice (LoM) to demonstrate efficient in vivo replication of all recently emerged human coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2) and two highly relevant endogenous pre-pandemic SARS-like bat coronaviruses.
> Our results show that therapeutic and prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently in phase II–III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and thus has significant potential for the prevention and treatment of COVID-19.
EIDD-2801 (Molnupiravir [2]) is an oral antiviral while monoclonal antibody treatment requires intravenous delivery.
https://medium.com/microbial-instincts/the-verdict-of-3-new-...
From link:
> In conclusion, this meta-analysis clearly shows that HCQ alone is not effective for the treatment of Covid-19 patients and that the combination of HCQ and AZI increases the risk of mortality.
> Failure of HCQ to show viral clearance or clinical benefits with additional adverse effects outweigh its protective effect from radiological progression in non-severe Covid-19 patients.
> HCQ is associated with more total AEs [adverse effects], gastrointestinal AEs, and skin and subcutaneous tissue AEs compared with placebo or no intervention in the overall population
If by decent result you mean "it certainly does something but it's not even clear if it's good or bad", then sure, it's decent.
HCQ is still being studied as it might be useful it some particular scenarios, but its general use is discouraged and understandably so.
TL;DR: Hydroxychloroquine worked in the lab with cells that have ACE2 but lacked TMPRSS2. Human trials failed because SARS-CoV-2 can enter the cell via a 2nd pathway assisted by TMPRSS2. Hydroxychloroquine probably works in combination with Camostat.
[1] https://youtu.be/l-YyM-0CHZU?t=3m14s
[2] https://journals.plos.org/plospathogens/article?id=10.1371/j...